With wildfires burning and Covid-19 spreading, can California afford stem cell research? Voters are set to decide
By Usha Lee McFarling,
STAT
| 10. 26. 2020
LOS ANGELES — This Election Day, California voters are being asked to replenish funding for the state’s ambitious stem cell research program, with a well-financed campaign that’s making heady promises about curing diabetes, paralysis, cancer, and Parkinson’s and Alzheimer’s diseases.
Backers of Proposition 14 also cast it as a job-creation measure, arguing the money it raises will boost the state economy by cementing the Golden State’s place as a leading incubator of successful biotech startups. But opponents say that amid the Covid-19 pandemic and wildfires, California has far more pressing needs.
In 2004, Californians approved a $3 billion ballot measure, Proposition 71, to create a new state agency to fund stem cell research at a time when President George W. Bush had banned federal funding for some of this work — if scientists used newly created embryonic stem cell lines. Now, even though the National Institutes of Health funds stem cell research to the tune of $2 billion a year, California residents are being asked to authorize the sale of $5.5 billion in general obligation bonds to pay for stem...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...